What is Kyverna Therapeutics, Inc.'s debt issuance proceeds?

Kyverna Therapeutics, Inc. (KYTX) reported debt issuance proceeds of $6.18M in Q4 2025.

What does debt issuance proceeds mean?

Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.

Kyverna Therapeutics, Inc. KYTX Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Cabot CorporationCBT

$9M-35.7%

Main Street CapitalMAIN

$531M+94.5%

Travel + LeisureTNL

$812M+28.5%

HES

Hess MidstreamHESM

$0-100%

Dave, Inc.DAVE

$193.08M—

MYR GroupMYRG

$48M-79.2%

Other financials

Income statement

See full

Operating income-$41.4M+12.7%

Net income-$39.7M+11.0%

EPS (diluted)-$0.66+35.9%

Balance sheet

See full

Cash & equivalents$32.2M-43.4%

Total debt$9.2M+32.1%

Total equity$195.6M-12.7%

Total assets$257.0M-1.4%

Cash flow

See full

Operating cash flow-$41.6M+7.4%

CapEx$2.0K-98.0%

Free cash flow-$33.5M+10.8%

Valuation

See full

Market cap$498.52M+276%

Enterprise value$475.49M+475%

Returns & leverage

See full

Return on equity-74.5%+74.4pp

Debt / equity0×0.0×

Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromDebtNetOfIssuanceCosts.

The official record: Kyverna Therapeutics, Inc.’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s debt issuance proceeds?: Kyverna Therapeutics, Inc. (KYTX) reported debt issuance proceeds of $6.18M in Q4 2025.
What does debt issuance proceeds mean?: Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.